ADM Tronics Signs Exclusive Deal To Market Its Products.

Business Editors

NORTHVALE, N.J.--(BUSINESS WIRE)--April 9, 2001

ADM Tronics Unlimited, Inc. (OTCBB - ADMT) has entered into an exclusive agreement with Pegasus Marketing, LLC to begin marketing a wide range of products and medical devices manufactured by ADM Tronics.

This is the first step in ADM Tronics' newly planned expansion of its core business operations through marketing and sales of its diversified products lines and therapeutic medical devices.

"We are very excited at the potential of this new sales and marketing effort with our new partners," stated Andre' Di Mino, COO of ADM Tronics. "This is the first of many new and creative business techniques which we plan to implement as we seek to grow our market share and expand upon our business model in these highly profitable fields."

Mr. Nelson Rodriguez, Executive Vice President of Pegasus Marketing, stated, "We are extremely motivated by the exciting opportunity of marketing such a quality line of products and medical devices provided to us by ADM Tronics. In particular, we believe the topical dermatological line to be an extraordinary group of products with remarkable results in our test marketing." Pegasus Marketing, LLC is a joint venture marketing and sales company created by ADM Tronics and a group of business entrepreneurs and professionals, all of whom with vast experience in diversified industries, rounding out this strategic alliance.

ADM Tronics Unlimited, Inc. is a technology based developer and manufacturer of a diversified line of products, categorized into three distinct market segments - therapeutic, non-invasive electronic medical devices, environmentally safe chemical products and innovative topical dermatological products.

Statements in this release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties (detailed in the Company's filings with the SEC) that could cause actual results to differ materially from estimated results.